- High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
- VitaminDWiki – Can get 50,000 IU Vitamin D anywhere on the globe 18+ Amazon vendors say to take it weekly
- VitaminDWiki – Bone Mineral Density and Vitamin D - many studies
- Why not just take high-dose vitamin D, etc. to prevent and treat Prostate Cancer?
7 Vitamin D Receptor and Prostate Cancer studies - VitaminDWiki -
5 studies in both categories Prostate Cancer and Omega-3 - 5+ VitaminDWiki Bone pages have CANCER in the title
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT
Cancer . 2024 Mar 23. doi: 10.1002/cncr.35275 PDF is behind a paywall
Luke J Peppone 1 2, Amber S Kleckner 3, Chunkit Fung 4, J Edward Puzas 2, Jennifer E Reschke 1, Eva Culakova 1, Julia Inglis 5, Charles Kamen 1, Jonathan W Friedberg 4, Michelle Janelsins 1, Karen Mustian 1, Charles E Heckler 1, Supriya Mohile 4Background: Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However, ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective interventions for ADT-induced bone loss are limited.
Methods: A phase 2 randomized controlled trial investigated the feasibility, safety, and preliminary efficacy of high-dose weekly vitamin D (HDVD, 50,000 IU/week) versus placebo for 24 weeks in patients with prostate cancer receiving ADT, with all subjects receiving 600 IU/day vitamin D and 1000 mg/day calcium. Participants were ≥60 years (mean years, 67.7), had a serum 25-hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months. At baseline and after intervention, dual-energy x-ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured.
Results: The HDVD group (N = 29) lost 1.5% BMD at the total hip vs. 4.1% for the low-dose group (N = 30; p = .03)
And 1.7% BMD at the femoral neck vs. 4.4% in the low-dose group (p = .06).
Stratified analyses showed that, for those with baseline 25-hydroxyvitamin D level <27 ng/mL, the HDVD group lost 2.3% BMD at the total hip vs 7.1% for the low-dose group (p < .01). Those in the HDVD arm showed significant changes in parathyroid hormone (p < .01), osteoprotegerin (p < 0.01), N-terminal telopeptide of type 1 collagen (p < 0.01) and C-terminal telopeptide of type 1 collagen (p < 0.01). No difference in adverse events or toxicity was noted between the groups.Conclusions: HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25-hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT.
64 References
- Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2007;177(1):17‐24. doi:10.1016/j.juro.2006.08.089
- Mohile SG, Lachs M, Dale W. Management of prostate cancer in the older man. Semin Oncol. 2008;35(6):597‐617. S0093‐7754(08)00186‐3 pii. doi:10.1053/j.seminoncol.2008.08.003
- Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70(3):235‐255. S1040‐8428(08)00216‐3 pii. doi:10.1016/j.critrevonc.2008.09.004
- Mohile SG, Petrylak DP. Management of asymptomatic rise in prostatic‐specific antigen in patients with prostate cancer. Curr Oncol Rep. 2006;8(3):213‐220. doi:10.1007/s11912‐006‐0022‐8
- Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low‐risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22(11):2141‐2149. JCO.2004.10.062 pii. doi:10.1200/JCO.2004.10.062
- Cianferotti L, Bertoldo F, Carini M, et al. The prevention of fragility fractures in patients with non‐metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget. 2017;8(43):75646‐75663. doi:10.18632/oncotarget.17980
- Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238‐244. doi:10.1001/jama.294.2.238
- Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.J Clin Endocrinol Metab. 2005;90(12):6410‐6417. doi:10.1210/jc.2005‐0183
- Hannan MT, Felson DT, Anderson JJ. Bone mineral density in elderly men and women: results from the Framingham osteoporosis study.J Bone Miner Res. 1992;7(5):547‐553. doi:10.1002/jbmr.5650070511
- Israeli RS, Ryan CW, Jung LL. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.J Urol. 2008;179(2):414‐423. doi:10.1016/j.juro.2007.09.028
- Slemenda CW, Christian JC, Reed T, Reister TK, Williams CJ, Johnston CC Jr. Long‐term bone loss in men: effects of genetic and environmental factors.Ann Intern Med. 1992;117(4):286‐291. doi:10.7326/0003‐4819‐117‐4‐286
- Panju AH, Breunis H, Cheung AM, et al. Management of decreased bone mineral density in men starting androgen‐deprivation therapy for prostate cancer.BJU Int. 2009;103(6):753‐757. doi:10.1111/j.1464‐410X.2008.08156.x
- Kim DK, Lee JY, Kim KJ, et al. Effect of androgen‐deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta‐analysis. J Clin Med. 2019;8(1):113. doi:10.3390/jcm8010113
- Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653‐1659. doi:10.1200/JCO.2003.09.534
- Smith MR. Changes in fat and lean body mass during androgen‐deprivation therapy for prostate cancer. Urology. 2004;63(4):742‐745. doi:10.1016/j.urology.2003.10.063
- Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102(1):44‐47. doi:BJU7539 pii. doi:10.1111/j.1464‐410X.2008.07539.x
- Melton LJ, 3rd, Lieber MM, Atkinson EJ, et al. Fracture risk in men with prostate cancer: a population‐based study.J Bone Miner Res. 2011;26(8):1808‐1815. doi:10.1002/jbmr.405
- Ziaran S, Goncalves FM, Breza JS. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocr Regul. 2011;45(4):199‐204. doi:10.4149/endo_2011_04_199
- van Oostwaard MM, van den Bergh JP, van de Wouw Y, Janssen‐Heijnen M, de Jong M, Wyers CE. High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. J Bone Oncol. 2023;38:100465. doi:10.1016/j.jbo.2022.100465
- Alibhai SMH, Zukotynski K, Walker‐Dilks C, et al. Bone health and bone‐targeted therapies for prostate cancer: a programme in evidence‐based care — Cancer Care Ontario Clinical Practice Guideline. Clin Oncol. 2017;29(6):348‐355. doi:10.1016/j.clon.2017.01.007
- Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005‐1007. doi:10.1097/01.ju.0000024395.86788.cc
- Higano CS. Androgen‐deprivation‐therapy‐induced fractures in men with nonmetastatic prostate cancer: what do we really know?Nat Clin Pract Urol. 2008;5(1):24‐34. doi:10.1038/ncpuro0995
- van Cann T, Loyson T, Verbiest A, et al. Incidence of medication‐related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer. 2018;26(3):869‐878. doi:10.1007/s00520‐017‐3903‐5
- van Poznak CH, Unger JM, Darke AK, et al. Osteonecrosis of the jaw in patients with cancer receiving zoledronic acid for bone metastases, SWOG S0702, NCT00874211. 2019
- Vargas‐Franco JW, Castaneda B, Redini F, Gomez DF, Heymann D, Lezot F. Paradoxical side effects of bisphosphonates on the skeleton: what do we know and what can we do? J Cell Physiol. 2018;233(8):5696‐5715. doi:10.1002/jcp.26465
- Skjodt MK, Frost M, Abrahamsen B. Side effects of drugs for osteoporosis and metastatic bone disease. Br J Clin Pharmacol. 2019;85(6):1063‐1071. doi:10.1111/bcp.13759
- Gillessen S, Fredy Von Moos RA, Hayoz S, et al. Incidence of hypocalcemia in patients with castration‐resistant prostate cancer treated with denosumab: data from a non‐inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE). 2019:
- Fatoye F, Smith P, Gebrye T, Yeowell G. Real‐world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049. doi:10.1136/bmjopen‐2018‐027049
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures; 2010. Accessed 23 July 2019. https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐c...
- Travis RC, Perez‐Cornago A, Appleby PN, et al. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin d and prostate cancer risk. Cancer Res. 2019;79(1):274‐285. doi:10.1158/0008‐5472.CAN‐18‐2318
- Khan QJ, Reddy PS, Kimler BF, et al. Effect of vitamin D supplementation on serum 25‐hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.Breast Cancer Res Treat. 2010;119(1):111‐118. doi:10.1007/s10549‐009‐0495‐x
- Mustian KM, Palesh O, Sprod L, et al. YOCAS® yoga significantly improves sleep quality (SQ) and circadian rhythm in 410 cancer survivors. Ann Behav Med. 2011:s5.
- Rastelli AL, Taylor ME, Gao F, et al. vitamin D and aromatase inhibitor‐induced musculoskeletal symptoms (AIMSS): a phase II, double‐blind, placebo‐controlled, randomized trial.Breast Cancer Res Treat. 2011;129(1):107‐116. doi:10.1007/s10549‐011‐1644‐6
- Malihi Z, Lawes CMM, Wu Z, et al. Monthly high‐dose vitamin D3 supplementation and self‐reported adverse events in a 4‐year randomized controlled trial. Clin Nutr. 2018;38(4):1581‐1587. doi:10.1016/j.clnu.2018.07.034
- Bouillon R, Manousaki D, Rosen C, Trajanoska K, Rivadeneira F, Richards JB. The health effects of vitamin D supplementation: evidence from human studies. Nat Rev Endocrinol. 2022;18(2):96‐110. doi:10.1038/s41574‐021‐00593‐z
- Shapiro CL, Poznak CV, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO Clinical Practice Guideline. J Clin Oncol. 2019;37(31):2916‐2946. doi:10.1200/jco.19.01696
- Ganji V, Tangpricha V, Zhang X. Serum vitamin D concentration ≥75 nmol/L is related to decreased cardiometabolic and inflammatory biomarkers, metabolic syndrome, and diabetes; and increased cardiorespiratory fitness in US adults. Nutrients. 2020;12(3):730. doi:10.3390/nu12030730
- Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439‐443. doi:10.1007/s001980050030
- Holick MF, Binkley NC, Bischoff‐Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2011;96(7):1911‐1930. doi:10.1210/jc.2011‐0385
- Pilz S, Trummer C, Theiler‐Schwetz V, et al. Critical appraisal of large vitamin D randomized controlled trials. Nutrients. 2022;14(2):14. doi:10.3390/nu14020303
- Treadwell J, Uhl S, Tipton K, et al. Example MIDs for specific clinical topics. Assessing Equivalence and Noninferiority; 2012. Internet.
- Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5(1):65‐74. doi:10.1007/s11926‐003‐0085‐6
- Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2‐19. doi:10.1016/j.bone.2011.04.022
- Suresh E, Abrahamsen B. Denosumab: a novel antiresorptive drug for osteoporosis. Cleve Clin J Med. 2015;82(2):105‐114. doi:10.3949/ccjm.82a.13173
- Laird E, Ward M, McSorley E, Strain JJ, Wallace J. vitamin D and bone health: potential mechanisms. Nutrients. 2010;2(7):693‐724. doi:10.3390/nu2070693
- Takahashi N, Udagawa N, Suda T. vitamin D endocrine system and osteoclasts. BoneKEy Rep. 2014;3. doi:10.1038/bonekey.2013.229
- Karim Y, Turner C, Dalton N, et al. The relationship between pro‐resorptive inflammatory cytokines and the effect of high dose vitamin D supplementation on their circulating concentrations. Int Immunopharm. 2013;17(3):693‐697. doi:10.1016/j.intimp.2013.08.010
- Rossini M, Adami S, Viapiana O, et al. Dose‐dependent short‐term effects of single high doses of oral vitamin D(3) on bone turnover markers. Calcif Tissue Int. 2012;91(6):365‐369. doi:10.1007/s00223‐012‐9637‐y
- Rossini M, Gatti D, Viapiana O, et al. Short‐term effects on bone turnover markers of a single high dose of oral vitamin D(3). J Clin Endocrinol Metabol. 2012;97(4):E622‐E626. doi:10.1210/jc.2011‐2448
- Kogawa M, Anderson PH, Findlay DM, Morris HA, Atkins GJ. The metabolism of 25‐(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol. 2010;121(1):277‐280. doi:10.1016/j.jsbmb.2010.03.048
- Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic metabolism of 25(OH)‐vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology. 2010;151(10):4613‐4625. doi:10.1210/en.2010‐0334
- Takahashi N, Udagawa N, Suda T. vitamin D endocrine system and osteoclasts. BoneKEy Rep. 2014;3:495. doi:10.1038/bonekey.2013.229
- Sahota O, Hosking D. Update on calcium and vitamin D metabolism. Curr Orthop. 1999;13(1):53‐63. doi:10.1016/S0268‐0890(99)90085‐3
- Baldock PA, Thomas GP, Hodge JM, et al. vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res. 2006;21(10):1618‐1626. doi:10.1359/jbmr.060714
- Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony‐stimulating factor. Bone. 1999;25(5):517‐523. doi:10.1016/s8756‐3282(99)00210‐0
- Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen‐deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745‐755. doi:10.1056/NEJMoa0809003
- Durden E, Pinto L, Lopez‐Gonzalez L, Juneau P, Barron R. Two‐year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States. Arch Osteoporosis. 2017;12(1):22. doi:10.1007/s11657‐017‐0316‐5
- Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Elsevier; 2009:632‐638.
- Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis‐‐for whom and for how long? N Engl J Med. 2012;366(22):2051‐2053. doi:10.1056/NEJMp1202623
- Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis‐‐where do we go from here? N Engl J Med. 2012;366(22):2048‐2051. doi:10.1056/NEJMp1202619
- Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is >/=33 ng/ml. Osteoporos Int. 2012;23(10):2479‐2487. doi:10.1007/s00198‐011‐1868‐7
- Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009;85(5):398‐404. doi:10.1007/s00223‐009‐9295‐x
- Powe CE, Evans MK, Wenger J, et al. vitamin D–binding protein and vitamin D status of Black Americans and White Americans. N Engl J Med. 2013;369(21):1991‐2000. doi:10.1056/NEJMoa1306357
- Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK. Effect of high‐dose vitamin D Supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA. 2019;322(8):736‐745. doi:10.1001/jama.2019.11889
VitaminDWiki – Can get 50,000 IU Vitamin D anywhere on the globe 18+ Amazon vendors say to take it weekly
VitaminDWiki – Bone Mineral Density and Vitamin D - many studies
Why not just take high-dose vitamin D, etc. to prevent and treat Prostate Cancer?
Overview Prostate Cancer and Vitamin D contains:
All items in category Prostate Cancer and Vitamin D103 items Examples
- Overview Prostate Cancer and Vitamin D
- Prostate Cancer long term survival 1.7 X more likely if high level of vitamin D – Jan 2016
- High PSA readings with Prostate Cancer 4 times more likely if poor Vitamin D receptor – March 2016
- Aggressive Prostate Cancer in blacks with low vitamin D – 7X more likely if added Calcium – Jan 2017
- Probably better than 40% reduction if 40 ng of Vitamin D and minimize Calcium
- Prostate cancer in black men is 1.6 times more likely if a poor Vitamin D Receptor – Feb 2017
- Probably better than 40% reduction if 40 ng of Vitamin D and improve Receptor activation (8 ways)
- Low-Grade Prostate Cancer 70 percent less likely to progress if good level of Omega-3 – June 2018
- Might prevent Prostate Cancer with Omega-3 and Vitamin D
- Prostate Cancer PSA reduced by 60 ng of Vitamin D, Vitamin B complex, Omega-3, Curcumin and diet – June 2021
- The use of Vitamin D to prevent prostate cancer doubled in a decade – May 2019
- Prostate cancer patients in Jamaica were 5X more likely to die of PC if low vitamin D - Sept 2022
- Can take 40,000 IU of vitamin D daily before prostate cancer surgery – RCT March 2013
The Meta-analysis of Prostate Cancer
- 1.5X more likely to die of Prostate Cancer if low vitamin D when initially diagnosed – meta-analysis March 2024
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Variety of Vitamin D forms treat Prostate Cancer – RCT Review April 2019
- Prostate Cancer death 40 percent less likely if 40 ng level of vitamin D – Meta-analysis Oct 2018
- Prostate cancer risk increase with Vitamin D (other studies disagree) – meta-analysis Jan 2018
- Meta-graphs of vitamin D and Cancer – Dec 2011
- Risk of Prostate Cancer weakly associated with vitamin D - meta-analysis March 2011
- 16 percent less Prostate Cancer sometimes for each 10 ng vitamin D increase - meta-analysis Jan 2011
- Meta-analysis found vitamin D association with colon but not prostate nor breast cancer May 2010
Vitamin D prevents/treats Prostate Cancer much better when there is not excess Calcium
Prostate cancer risk increase with Vitamin D (other studies disagree) – meta-analysis Jan 2018 prevention
Prostate cancer reduced when 4000 IU vitamin D was added– Hollis RCT April 2015 treatment
7X increase in stage IV Prostate Cancer survival when vitamin D greater than 32 ng – May 2013
Never too late to have vitamin D - loading dose is great before Prostate Surgery
7 Vitamin D Receptor and Prostate Cancer studies__ automatically updated
- Book: Sunlight, UV, Vitamin D and Receptor, Skin and other Cancers - Dec 2020
- Prostate Cancer associated with various genes, including Vitamin D Receptor and CYP24A1 – Nov 2019
- Prostate surgery outcomes vary with Vitamin D Receptors– May 2017
- Prostate cancer in black men is 1.6 times more likely if a poor Vitamin D Receptor – Feb 2017
- Aggressive Prostate Cancer in blacks with low vitamin D – 7X more likely if added Calcium – Jan 2017
- High PSA readings with Prostate Cancer 4 times more likely if poor Vitamin D receptor – March 2016
- 2X less prostate cancer in A-A with low Calcium is due vitamin D receptor gene – July 2013
- The Role of Resveratrol in Cancer Therapy – Dec 2017
- Needing a high level of vitamin D is a good clue that the Vitamin D Receptor is deactivated
- A poor Vitamin D Receptor is associated with many cancers (oral cancer in this case) – Jan 2019
- Cancer and the Vitamin D Receptor, a primer – Sept 2017
VitaminDWiki -
5 studies in both categories Prostate Cancer and Omega-3 This list is automatically updated
- 2.5 X reduced risk of cancer in 70 year-olds by a small amount of Vitamin D, Omega-3 and exercise – RCT April 2022
- Prostate Cancer PSA reduced by 60 ng of Vitamin D, Vitamin B complex, Omega-3, Curcumin and diet – June 2021
- Men with High Omega-3 ratio 3 times less likely to have high grade prostate cancer – July 2019
- Low-Grade Prostate Cancer 70 percent less likely to progress if good level of Omega-3 – June 2018
- Prostate Cancer treatment (Vitamin D, Omega-3, Tumeric) RCT ending Dec 2018
5+ VitaminDWiki Bone pages have CANCER in the title
This list is automatically updated
Items found: 550,000 IU of Vitamin D weekly greatly decreased bone loss from prostate cancer therapy - RCT March 2024929 visitors, last modified 24 Mar, 2024, This page is in the following categories (# of items in each category)- VitaminDWiki -